Sands Capital, established in 1992, is an independent, employee-owned investment management firm based in Arlington, Virginia. It specializes in growth equity investments, focusing on both public and private markets globally. The firm's investment approach is centered around rigorous, bottom-up fundamental research to identify high-quality growth businesses across various sectors, including technology, healthcare, and consumer goods. Sands Capital offers its services to a diverse range of clients, such as pension plans, endowments, foundations, and high-net-worth individuals. It operates through two affiliates: Sands Capital Management for public market investments and Sands Capital Ventures for private market investments. The firm aims to provide long-term, active investment strategies that add value and enhance clients' wealth over time.
1000 Wilson Blvd. Suite 3000 Arlington, VA 22209, USA
Ian Barnes
Managing Director
Matthew Buckley
Senior Research Associate
Brian Christiansen
Executive Managing Director, Senior Portfolio Manager and Research Analyst
Christopher Eng
Principal
Kumar Gautam
Partner
Michael J. Ginder
Partner
Michael Graninger
Managing Partner
Michael Graninger
Partner
Nicholas Graziano
Principal, Portfolio Services
David Levanson
Senior Portfolio Manager, Research Analyst and Executive Managing Director
Barron B. Martin, Jr.
Managing Partner
Annie McCormick
Director, Client Service
Mark McGovern
Venture Partner
Dana M. McNamara
Executive Managing Director and Chief Administrative Officer
Jake Merrill, CFA
Principal
Barron Martin
Research Analyst
Gene Riechers
Venture Partner
Frank M. Sands, Jr.
CEO, CIO
Marina Serenbetz
Partner
Shreya Singh
Associate
Erin Soule
Managing Director and Head of Private Markets Finance and Operations
Michael Sramek
Managing Director, Research Analyst and Senior Portfolio Manager
Christy Steele
Principal
Past deals in Infants
Vitara Biomedical
Series B in 2024
Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.
Vitara Biomedical
Series B in 2022
Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.